EarningsQ2 2026 Earnings Report
MX:CC Q2 2026 EPS Results
Actual EPS$7.10
Consensus EPS$8.27
Beat/MissMissed by -$1.17
One Year Ago EPS$9.81
MX:CC Q2 2026 Revenue Results
Actual Revenue$26.91B
Expected Revenue$27.92B
Beat/MissMissed by -$1.01B
YoY Revenue Growth-1.49%
Earnings Announcement Details
QuarterQ2 2026
Date08/04/2026
TimeAfter Close
Conference CallTuesday, August 4, 2026
MX:CC Upcoming Earnings
Chemours Company's next earnings date is estimated for October 28, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:CC Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted meaningful operational and commercial progress—Q2 adjusted EBITDA beat expectations, TT pricing momentum (≈5% YTD), APM Performance Solutions growth (+8% YoY) and strong cash generation including a ~$270M debt repayment—while also acknowledging notable near-term headwinds, especially TSS aftermarket destocking (pre-buy impact ≈$65M and ~25% YoY market drop), APM volume effects from a prior line closure and TT volume softness amid inflationary input costs. Management reiterated a constructive multi-year view (Pathway to Thrive, $1B adjusted EBITDA ambition) and provided a measured FY 2026 outlook, but near-term guidance incorporates expected sequential declines and ongoing uncertainties.Company Guidance
Q2 Adjusted EBITDA Outperformance and Pricing Momentum
Adjusted EBITDA exceeded expectations in Q2 driven by stronger operational performance, an improved product mix in APM and pricing gains in Titanium Technologies; company announced three TiO2 price increases since December 2025, contributing to approximately a 5% year-to-date price increase in TT.
APM Performance Solutions Growth and Product Traction
APM's Performance Solutions net sales grew 8% year-over-year; order book strength driven by data center and semiconductor end markets; early sampling sales of 2-phase liquid cooling products recorded and product trials increased ~70% year-over-year, indicating early commercial traction in attractive growth markets.
Strong Cash Generation and Debt Reduction
Chemours continued to strengthen its balance sheet: repaid close to $270 million of its 2028 euro term loan in Q2 (an additional $103 million beyond prior communication) and is prioritizing debt repayment using organic cash flow and proceeds from the Kuan Yin land sale; Q3 free cash flow is expected to be at least $50 million and the company reported >40% free cash flow conversion in the quarter, with FY conversion guidance above 25%.
Full-Year 2026 Guidance and Long-Term Targets
Full-year 2026 outlook: net sales growth of +1% to +5% versus 2025 and adjusted EBITDA guidance of $775 million to $825 million; FY capital expenditures $250 million to $280 million; target net leverage around 3.8x adjusted EBITDA by end of 2026; long-term ambition reiterated to achieve at least $1 billion of annual adjusted EBITDA and >40% free cash flow conversion as Pathway to Thrive progresses.
Business-Level Earnings and Operational Progress
TSS adjusted EBITDA increased year-over-year with margin expansion driven by pricing and timing benefits; TT adjusted EBITDA improved year-over-year and management expects TT Q3 net sales to rise sequentially (low- to mid-single-digit) with Q3 TT adjusted EBITDA guided to $70M–$80M; APM expected to return to improved operating levels as Washington Works normalizes, with Q3 APM adjusted EBITDA guided to $20M–$30M.
MX:CC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed